{
    "organizations": [],
    "uuid": "bb0582c50aeab1ea57830c64119fe197862e03e1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-genentech-says-follow-up-phase-3-d/brief-genentech-says-follow-up-phase-3-data-showed-alecensa-reduced-risk-of-disease-progression-by-57-pct-idUSFWN1SN110",
    "ord_in_thread": 0,
    "title": "BRIEF-Genentech Says Follow-Up Phase 3 Data Showed Alecensa Reduced Risk Of Disease Progression By 57 Pct",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Genentech:\n* FOLLOW-UP PHASE III DATA SHOWED GENENTECHâ€™S ALECENSA HELPED PEOPLE WITH ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER LIVE A MEDIAN OF ALMOST THREE YEARS WITHOUT THEIR DISEASE WORSENING OR DEATH\n* GENENTECH - FOLLOW-UP PHASE III DATA SHOWED ALECENSA REDUCED RISK OF DISEASE PROGRESSION/DEATH BY 57 PERCENT VERSUS CRIZOTINIB IN PEOPLE WITH ALK-POSITIVE METASTATIC NSCLC Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-17T05:16:00.000+03:00",
    "crawled": "2018-05-17T01:45:53.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "genentech",
        "phase",
        "iii",
        "data",
        "showed",
        "genentech",
        "alecensa",
        "helped",
        "people",
        "metastatic",
        "cell",
        "lung",
        "cancer",
        "live",
        "median",
        "almost",
        "three",
        "year",
        "without",
        "disease",
        "worsening",
        "death",
        "genentech",
        "phase",
        "iii",
        "data",
        "showed",
        "alecensa",
        "reduced",
        "risk",
        "disease",
        "percent",
        "versus",
        "crizotinib",
        "people",
        "metastatic",
        "nsclc",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}